RAPT Therapeutics, Inc. news centered on clinical-stage immunology drug development for inflammatory and immunological diseases, including ozureprubart, formerly RPT904, an anti-IgE therapy evaluated in IgE-mediated food allergy and chronic spontaneous urticaria. Company updates covered clinical trial initiation and data releases, collaboration-related development with Shanghai Jeyou Pharmaceutical, financial results, public equity financing, and investor conference presentations.
The company's public-company history also includes a completed merger in which RAPT became a wholly owned subsidiary of GlaxoSmithKline LLC, followed by Nasdaq delisting and Exchange Act deregistration filings. Corporate updates provide historical context for its former Nasdaq-listed common stock and immunology pipeline disclosures.
Summary not available.
Summary not available.
Summary not available.
Summary not available.
Summary not available.
Summary not available.
Summary not available.
Summary not available.
Summary not available.
Summary not available.